GO:0098761 cellular response to interleukin-7: Immune Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0098761 (cellular response to interleukin-7) describes all molecular and cellular changes triggered when a cell receives an IL-7 stimulus.
• IL-7 signaling is essential for T-cell survival, proliferation, and memory formation, and it shapes both lymphoid and innate-like immune responses.
• The pathway is being actively exploited in cancer immunotherapy, including CAR-T cells engineered to secrete IL-7 and CCL19, and in oncolytic viral therapy for glioblastoma.
• IL-7 also acts as an adjuvant to enhance vaccine-induced humoral immunity and to overcome inhibitory networks in adoptive T-cell therapy.
• Key genes in this response include IL7, IL7R, JAK1/3, STAT5A/B, and downstream effectors such as BCL2 and MYC, which are frequently studied using CRISPR knockout, knock-in, and overexpression models.
• Studying GO:0098761 requires integrated methods such as phospho-flow, RNA-seq, and CRISPR screens to dissect context-dependent signaling outcomes.
Description
The Gene Ontology term GO:0098761, cellular response to interleukin-7, defines the collection of cellular processes that change in state or activity after a cell encounters interleukin-7 (IL-7). IL-7 is a pleiotropic cytokine produced by stromal cells in lymphoid organs, and its receptor is expressed on T cells, B cells, and innate-like lymphocytes. The cellular response to IL-7 encompasses rapid signaling events, transcriptional reprogramming, metabolic adaptation, and long-term survival or differentiation decisions. Because IL-7 signaling is central to lymphocyte homeostasis and immune memory, understanding this GO term is critical for immunology, vaccine design, and cancer immunotherapy. Research into GO:0098761 has revealed that IL-7 responses are not uniform: they vary by cell type, developmental stage, and inflammatory context. For example, IL-7 primes bystander CD8 tumor-infiltrating lymphocytes to enhance T cell engager immunotherapy, while in skin-resident memory T cells, divergent molecular networks downstream of IL-7 shape functional heterogeneity. These findings highlight the need for precise experimental models to dissect the pathway. This article provides a research-grade overview of GO:0098761, covering its definition, core mechanisms, key genes, disease relevance, and state-of-the-art methods including CRISPR-based models. All statements are grounded in published literature to support reproducibility and generative-AI retrieval.
cellular response to interleukin-7 At A Glance
| GO ID | GO:0098761 |
|---|---|
| GO term | cellular response to interleukin-7 |
| Ontology | biological_process |
| Synonym | cellular response to IL-7 |
| Major function | Mediates cellular changes triggered by IL-7, including survival, proliferation, and gene expression reprogramming |
| Related cytokine | Interleukin-7 (IL-7), a stromal-derived cytokine |
| Primary receptor | IL-7 receptor (IL-7R), composed of IL-7Ralpha and common gamma chain |
| Key signaling pathways | JAK-STAT, PI3K-AKT, and MAPK cascades |
| Cell types involved | T cells, B cells, innate-like lymphocytes, and tumor-infiltrating lymphocytes |
What Is GO:0098761?
In our own words, GO:0098761 describes any process that results in a change in state or activity of a cell (such as movement, secretion, enzyme production, or gene expression) as a result of an interleukin-7 stimulus. It is a biological process term that captures the cellular response to IL-7, also known as the cellular response to IL-7.
Why Is cellular response to interleukin-7 Important in Cell Biology?
GO:0098761 is important because IL-7 signaling is a master regulator of lymphocyte survival, proliferation, and memory, and its manipulation has direct therapeutic potential in cancer, infectious disease, and vaccination. Dysregulated IL-7 responses contribute to immune pathology, while engineered IL-7 signals can boost antitumor immunity and vaccine efficacy. Understanding the cellular response to IL-7 at a molecular level enables rational design of immunotherapies and CRISPR-based disease models.
• IL-7 signaling is essential for T-cell development and peripheral T-cell survival.
• The pathway promotes memory T-cell formation and long-term immune protection.
• IL-7-secreting CAR-T cells improve antitumor efficacy in glypican-3 or mesothelin-positive tumors.
• Long-acting IL-7 enhances oncolytic viral therapy in glioblastoma models.
• IL-7 priming of bystander CD8 tumor-infiltrating lymphocytes optimizes T cell engager immunotherapy.
• IL-7 protects against bacterial respiratory infection by promoting IL-17A-producing innate T-cell responses.
• Adjuvant IL-7 antagonizes inhibitory networks to enhance immunotherapies.
• Overexpression of IL-7 extends humoral immune responses induced by rabies vaccination.
• The pathway is a target for CRISPR screens to identify context-specific regulators.
• GO:0098761 is relevant to autoimmune diseases, immunodeficiency, and cancer immunology.
What Happens During cellular response to interleukin-7?
IL-7 Binding and Receptor Activation
In simple terms: IL-7 docks onto its receptor on the cell surface, switching it on.
The cellular response to IL-7 begins when IL-7 binds to the IL-7 receptor (IL-7R), a heterodimer of IL-7Ralpha (CD127) and the common gamma chain (CD132). This binding induces conformational changes that activate receptor-associated Janus kinases (JAK1 and JAK3). Activated JAKs then phosphorylate tyrosine residues on the receptor, creating docking sites for downstream signaling molecules.
JAK-STAT Signaling and Transcriptional Reprogramming
In simple terms: Signals travel to the nucleus to turn genes on or off.
Phosphorylated STAT5 (STAT5A and STAT5B) translocates to the nucleus and drives transcription of genes that promote survival, proliferation, and differentiation. This transcriptional program includes upregulation of anti-apoptotic proteins such as BCL2 and pro-proliferative factors like MYC. In skin-resident memory T cells, divergent molecular networks downstream of IL-7 signaling program functionally distinct subsets.
PI3K-AKT and MAPK Pathway Activation
In simple terms: Other signaling routes help the cell grow and survive.
In addition to JAK-STAT, IL-7 activates the PI3K-AKT pathway, which promotes metabolic fitness and survival, and the MAPK cascade, which can influence proliferation and cytokine production. These pathways cooperate to shape the overall cellular response to IL-7.
Metabolic Adaptation and Survival
In simple terms: The cell adjusts its metabolism to stay alive and grow.
IL-7 signaling supports metabolic reprogramming, including increased glucose uptake and mitochondrial function, to meet the bioenergetic demands of activated lymphocytes. This metabolic adaptation is critical for T-cell survival and memory formation.
Cytokine Production and Effector Functions
In simple terms: The cell may start secreting other signals to coordinate immune responses.
In some contexts, IL-7 promotes the production of effector cytokines such as IL-17A by innate T cells, contributing to protection against bacterial respiratory infection. IL-7 also enhances the antitumor efficacy of T cell engager immunotherapy by priming bystander CD8 tumor-infiltrating lymphocytes.
Key Genes Involved in GO:0098761 cellular response to interleukin-7
The following genes and proteins are central to the cellular response to interleukin-7 (GO:0098761) and are frequently studied using CRISPR-based models.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL7 | Encodes interleukin-7 cytokine | Ligand that initiates the response; overexpressed in immunotherapy |
| IL7R | Encodes IL-7 receptor alpha chain | Mediates IL-7 binding and signaling; target for knockout studies |
| JAK1 | Janus kinase 1 | Phosphorylates STAT proteins downstream of IL-7R |
| JAK3 | Janus kinase 3 | Associates with common gamma chain; essential for IL-7 signaling |
| STAT5A | Signal transducer and activator of transcription 5A | Transcription factor driving IL-7-responsive gene expression |
| STAT5B | Signal transducer and activator of transcription 5B | Transcription factor driving IL-7-responsive gene expression |
| BCL2 | Anti-apoptotic protein | Promotes survival downstream of IL-7 |
| MYC | Transcription factor | Drives proliferation in response to IL-7 |
| PIK3CA | PI3K catalytic subunit alpha | Activates AKT pathway downstream of IL-7 |
| AKT1 | Serine/threonine kinase | Promotes survival and metabolism |
| MAPK1 | Mitogen-activated protein kinase 1 | Influences proliferation and cytokine production |
| CCL19 | Chemokine ligand 19 | Co-expressed with IL-7 in engineered CAR-T cells to enhance efficacy |
| GPC3 | Glypican-3 | Tumor antigen targeted in IL-7-secreting CAR-T therapy |
| MSLN | Mesothelin | Tumor antigen targeted in IL-7-secreting CAR-T therapy |
| CD8A | CD8 alpha chain | Marker of cytotoxic T cells responding to IL-7 |
| IL17A | Interleukin-17A | Effector cytokine induced by IL-7 in innate T cells |
| FOXP3 | Forkhead box P3 | Regulatory T cell transcription factor potentially influenced by IL-7 |
| CD127 | IL-7 receptor alpha (protein) | Surface marker for IL-7 responsiveness |
How Is cellular response to interleukin-7 Regulated?
The cellular response to interleukin-7 is tightly regulated at multiple levels. Receptor expression is controlled by developmental and inflammatory cues, and IL-7Ralpha (CD127) downregulation is a hallmark of chronic inflammation. Signaling is negatively regulated by SOCS proteins and phosphatases that dampen JAK-STAT activity. Additionally, IL-7 signaling cross-talks with other cytokine pathways, and its strength and duration influence cell fate decisions. In immunotherapy settings, engineered IL-7 secretion can overcome inhibitory networks and enhance T-cell function.
cellular response to interleukin-7 and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL7 | Cancer immunotherapy, vaccine adjuvant | Overexpression in CAR-T cells or viral vectors |
| IL7R | Immunodeficiency, autoimmunity | Knockout or point mutation in T cells |
| JAK3 | Severe combined immunodeficiency | Knockout in lymphoid cell lines |
| STAT5B | Immune dysregulation | Knock-in of patient mutations |
| IL17A | Bacterial respiratory infection | Knockout in innate T cells |
Cancer Immunotherapy
IL-7 signaling is exploited in cancer immunotherapy to boost T-cell survival and antitumor activity. CAR-T cells engineered to secrete IL-7 and CCL19 show improved efficacy against glypican-3 or mesothelin-positive tumors. Long-acting IL-7 enhances oncolytic viral therapy in glioblastoma, and IL-7 priming of bystander CD8 tumor-infiltrating lymphocytes optimizes T cell engager immunotherapy. Adjuvant IL-7 antagonizes inhibitory networks to enhance immunotherapies.
Infectious Disease and Vaccination
IL-7 protects against bacterial respiratory infection by promoting IL-17A-producing innate T-cell responses. Overexpression of IL-7 extends the humoral immune response induced by rabies vaccination, suggesting its use as a vaccine adjuvant.
Immune Memory and Tissue Residency
Divergent molecular networks downstream of IL-7 program functionally distinct CD8+ skin-resident memory T cells, highlighting its role in tissue immunity. Dysregulation of IL-7 responses may contribute to autoimmune diseases and immunodeficiency.
From cellular response to interleukin-7-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does IL-7R signaling drive T-cell survival? | IL7R knockout in primary T cells or cell lines |
| How do patient mutations in JAK3 affect IL-7 response? | Point mutation knock-in via CRISPR |
| Can IL-7 overexpression enhance antitumor immunity? | IL7 knock-in or overexpression in CAR-T cells |
| What genes are essential for IL-7-induced proliferation? | Genome-wide CRISPR knockout screen |
| How does IL-7 affect memory T-cell formation? | Tagged knock-in of IL7R for live imaging |
| Does IL-7 promote IL-17A production in innate T cells? | IL17A reporter knock-in in innate T cells |
How to Study the cellular response to interleukin-7 Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phospho-flow | Phosphorylated STAT5, AKT, MAPK | Signaling dynamics in T cells |
| RNA-seq | Transcriptional changes | Identify IL-7 target genes |
| CRISPR knockout screen | Gene essentiality | Discover regulators of IL-7 response |
| Proteomics | Protein expression and modifications | Map signaling networks |
| ChIP-seq | STAT5 binding sites | Identify direct transcriptional targets |
| Metabolic assays | Glucose uptake, mitochondrial function | Assess metabolic adaptation |
| Flow cytometry | Surface markers, cytokine production | Phenotype IL-7-responding cells |
| ELISA | Cytokine secretion | Measure IL-17A, IFN-gamma |
Phospho-Flow Cytometry
Phospho-flow allows quantification of phosphorylated STAT5, AKT, and MAPK at the single-cell level following IL-7 stimulation, revealing signaling dynamics in heterogeneous populations.
RNA Sequencing (RNA-seq)
RNA-seq captures global transcriptional changes induced by IL-7, identifying downstream target genes and pathways that define the cellular response.
CRISPR Screens
Genome-wide CRISPR knockout screens can identify genes required for IL-7-dependent proliferation or survival, uncovering novel regulators of GO:0098761.
Proteomics and Phosphoproteomics
Mass spectrometry-based proteomics measures protein expression and phosphorylation changes downstream of IL-7, providing a systems-level view of the response.
How CRISPR Can Be Used to Study GO:0098761 cellular response to interleukin-7
Knockout
CRISPR knockout of IL7R, JAK1, JAK3, or STAT5A/B can abolish the cellular response to IL-7, providing causal evidence for their roles. Knockout screens can identify novel genes required for IL-7-driven proliferation.
Point Mutation
Point mutations in JAK3 or STAT5B identified in patients can be introduced via CRISPR to model immunodeficiency or immune dysregulation and study their impact on IL-7 signaling.
Knock-in
Knock-in of tagged IL7R or reporter genes (e.g., IL17A-GFP) allows tracking of IL-7-responsive cells and their effector functions in vivo.
Overexpression
Overexpression of IL7 or IL7R via CRISPR activation or lentiviral delivery can enhance T-cell survival and antitumor activity, as shown in CAR-T and oncolytic virus models.
How EDITGENE Supports cellular response to interleukin-7 Research
Researchers studying cellular response to interleukin-7-related genes often need to determine whether a candidate gene is causally involved in IL-7 signaling, survival, or effector function. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for cellular response to interleukin-7 research.
Frequently Asked Questions About cellular response to interleukin-7
What is GO:0098761?
GO:0098761 is the Gene Ontology term for cellular response to interleukin-7, describing all cellular changes triggered by IL-7.
What genes are involved in cellular response to interleukin-7?
Key genes include IL7, IL7R, JAK1, JAK3, STAT5A, STAT5B, BCL2, and MYC.
How does IL-7 signaling work?
IL-7 binds IL-7R, activating JAK-STAT, PI3K-AKT, and MAPK pathways to promote survival, proliferation, and effector functions.
What diseases are linked to IL-7 signaling?
IL-7 signaling is linked to cancer immunotherapy, immunodeficiency, autoimmune diseases, and infectious disease.
How can CRISPR be used to study IL-7 responses?
CRISPR knockout, knock-in, and overexpression can validate gene function and model patient mutations in IL-7 pathways.
What methods measure cellular response to IL-7?
Phospho-flow, RNA-seq, proteomics, and CRISPR screens are commonly used.
Is IL-7 used in cancer therapy?
Yes, IL-7-secreting CAR-T cells and long-acting IL-7 enhance antitumor immunity in preclinical models.
What is the role of STAT5 in IL-7 signaling?
STAT5 is a transcription factor activated by JAKs that drives expression of survival and proliferation genes.
Can IL-7 boost vaccine responses?
Overexpression of IL-7 extends humoral immune responses to rabies vaccination in animal models.
What cell types respond to IL-7?
T cells, B cells, innate-like lymphocytes, and tumor-infiltrating lymphocytes respond to IL-7.
Conclusion
GO:0098761, cellular response to interleukin-7, is a central biological process that governs lymphocyte survival, proliferation, and effector function. Its molecular dissection has revealed key signaling nodes and gene networks that are now being harnessed for cancer immunotherapy, vaccine design, and infection control. Continued research using CRISPR-based models and multi-omics approaches will further illuminate context-specific mechanisms and therapeutic opportunities.
References
- 1. Pang N et al.. 2021. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin.. J Hematol Oncol 14(1):118 PMID: 34325726
- 2. Kittipatarin C et al.. 2007. Interlinking interleukin-7.. Cytokine 39(1):75-83 PMID: 17768066
- 3. Park SL et al.. 2023. Divergent molecular networks program functionally distinct CD8(+) skin-resident memory T cells.. Science 382(6674):1073-1079 PMID: 38033053
- 4. Li Y et al.. 2017. Overexpression of Interleukin-7 Extends the Humoral Immune Response Induced by Rabies Vaccination.. J Virol 91(7) PMID: 28100620
- 5. Li YD et al.. 2026. Long-acting interleukin-7 improves the efficacy of oncolytic viral therapy in glioblastoma.. Nat Commun 17(1) PMID: 41702890
- 6. Lee KJ et al.. 2024. IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy.. Cell Rep Med 5(5):101567 PMID: 38744277
- 7. Hassane M et al.. 2020. Interleukin-7 protects against bacterial respiratory infection by promoting IL-17A-producing innate T-cell response.. Mucosal Immunol 13(1):128-139 PMID: 31628425
- 8. Pellegrini M et al.. 2009. Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies.. Nat Med 15(5):528-36 PMID: 19396174
